Drug intelligence / Profile preview

yulanyou

Development stage: Preclinical
Lead developer: Peking University First Hospital

Overview

Yulanyou is a drug currently under investigation for the treatment of HP (Helicobacter pylori) infection. It is being studied in a prospective, open real-world clinical trial. Specific details regarding its mechanism of action, chemical composition, or modality are not publicly available from the provided context. The clinical trial is being conducted by Peking University First Hospital, Beijing Yuanxin Technology Group Co. LTD, and Beijing center Technology Group Limited, with some funding being self-provided.

Beyond the preview

Go deeper on yulanyou.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yulanyou.

Explore the full profile